Yamakawa T, Morimoto T, Sasa M, Numoto S, Monden Y
Second Department of Surgery, School of Medicine, University of Tokushima.
Jpn J Cancer Res. 1995 Nov;86(11):1035-40. doi: 10.1111/j.1349-7006.1995.tb03017.x.
Multiple sections of 40 consecutive cases with invasive ductal carcinoma of the breast, all of which bad wide intraductal cancerous extension, were examined by immunohistochemical analysis for evaluation of hormone dependency in several areas of breast cancer tissues. In this study, we examined the expression of pS2 protein in the central invasive area (CIV), central intraductal cancerous area (CDC) and forefront intraductal cancerous area (FDC). pS2 staining was positive in 52.5% (21/40) of CIV and a significant correlation was found between pS2 expression in CIV and the estrogen receptor status (ER). pS2 staining was positive in 77.5% of CDC and 85.0% of FDC, respectively. A majority (68.4%) of the cases that were negative pS2 in CIV were positive for pS2 in FDC. Moreover, the cases with noncomedo intraductal carcinoma in premenopausal status showed a higher positivity of pS2 expression in FDC than the cases with comedo-carcinoma, though the number of cases of comedo-carcinoma was limited. These findings suggest that endocrine therapy may be useful after breast conserving treatment regardless of the ER status of the primary tumor.
对40例连续的乳腺浸润性导管癌患者的多个切片进行了检查，所有病例均有广泛的导管内癌扩展，通过免疫组织化学分析评估乳腺癌组织多个区域的激素依赖性。在本研究中，我们检测了pS2蛋白在中央浸润区（CIV）、中央导管内癌区（CDC）和前沿导管内癌区（FDC）的表达。pS2染色在52.5%（21/40）的CIV中呈阳性，且CIV中pS2表达与雌激素受体状态（ER）之间存在显著相关性。pS2染色在CDC和FDC中分别为77.5%和85.0%阳性。CIV中pS2阴性的病例中，大部分（68.4%）在FDC中pS2为阳性。此外，绝经前状态的非粉刺性导管内癌病例在FDC中pS2表达的阳性率高于粉刺癌病例，尽管粉刺癌病例数量有限。这些发现表明，无论原发肿瘤的ER状态如何，保乳治疗后内分泌治疗可能有效。
